{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:01:05Z","timestamp":1777698065032,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.bmcl.2020.127393","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T11:39:25Z","timestamp":1594381165000},"page":"127393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase"],"prefix":"10.1016","volume":"30","author":[{"given":"Sameer P.","family":"Kawatkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Barlaam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kemmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Lamont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qibin","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Boiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Pike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Read","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ujjal","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanshan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Dry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Edmondson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"47","key":"10.1016\/j.bmcl.2020.127393_b0005","doi-asserted-by":"crossref","first-page":"32650","DOI":"10.1074\/jbc.M806340200","article-title":"Molecular mechanism of the SYK activation switch","volume":"283","author":"Tsang","year":"2008","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2020.127393_b0010","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4236\/jct.2014.51015","article-title":"SYK as a new therapeutic target in B-cell precursor acute lymphoblastic leukemia","volume":"5","author":"Uckun","year":"2014","journal-title":"J Cancer Ther"},{"key":"10.1016\/j.bmcl.2020.127393_b0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/oxfordjournals.jbchem.a002970","article-title":"Structure and function of SYK protein-tyrosine kinase","volume":"130","author":"Sada","year":"2001","journal-title":"J Biochem"},{"key":"10.1016\/j.bmcl.2020.127393_b0020","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/13543784.13.7.743","article-title":"Targeting SYK as a treatment for allergic and autoimmune disorders","volume":"13","author":"Wong","year":"2004","journal-title":"Expert Opin Investig Drug"},{"key":"10.1016\/j.bmcl.2020.127393_b0025","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-12-0397","article-title":"Quantitative Immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"18","author":"Bogusz","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2020.127393_b0030","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2007-07-100115","article-title":"SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2020.127393_b0035","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/blood-2011-02-333773","article-title":"SYK inhibition and response prediction in diffuse large B-cell lymphoma","volume":"118","author":"Cheng","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2020.127393_b0040","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2020.127393_b0045","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/13543784.2011.570329","article-title":"The SYK kinase as a therapeutic target in leukemia and lymphoma","volume":"20","author":"Efremov","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bmcl.2020.127393_b0050","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1517\/13543784.2011.611802","article-title":"The clinical development of FLT3 inhibitors in acute myeloid leukemia","volume":"20","author":"Knapper","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"145","key":"10.1016\/j.bmcl.2020.127393_b0055","first-page":"1","article-title":"SYK inhibitors in clinical development for hematological malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.bmcl.2020.127393_b0060","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nrrheum.2011.8","article-title":"Therapy: spleen tyrosine kinase inhibitors\u2014novel therapies for RA?","volume":"7","author":"Gomez-Puerta","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.bmcl.2020.127393_b0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000446879","article-title":"Spleen tyrosinekinase: a crucial player and potential therapeutic target in renal disease","volume":"133","author":"Ma","year":"2016","journal-title":"Nephron"},{"issue":"11","key":"10.1016\/j.bmcl.2020.127393_b0070","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1007\/s11095-014-1399-y","article-title":"Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma","volume":"31","author":"Pritchard","year":"2014","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.bmcl.2020.127393_b0075","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pupt.2007.06.002","article-title":"SYK inhibitors as treatment for allergic rhinitis","volume":"21","author":"Masuda","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.bmcl.2020.127393_b0080","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.tips.2014.05.007","article-title":"Getting SYK: spleen tyrosine kinase as a therapeutic target","volume":"35","author":"Geahlen","year":"2014","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.bmcl.2020.127393_b0085","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/exd.12986","article-title":"Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients","volume":"25","author":"Braegelmann","year":"2016","journal-title":"Exp Dermatol"},{"issue":"19","key":"10.1016\/j.bmcl.2020.127393_b0090","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2018-11-852491","article-title":"Fostamatinib for the treatment of chronic immune thrombocytopenia","volume":"133","author":"Connell","year":"2019","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bmcl.2020.127393_b0095","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of SYK with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2020.127393_b0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2015.10.005","article-title":"A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","volume":"54","author":"Flinn","year":"2016","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.bmcl.2020.127393_b0105","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1111\/bph.12559","article-title":"The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation","volume":"171","author":"Skinner","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.bmcl.2020.127393_b0110","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.175","article-title":"In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib","volume":"3","author":"Rolf","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.bmcl.2020.127393_b0115","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1016\/j.bmcl.2016.10.087","article-title":"Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)","volume":"26","author":"Lam","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2020.127393_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127433","article-title":"Discovery of a series of potent, selective, and orally bioavailable SYK inhibitors","author":"Grimster","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"issue":"10","key":"10.1016\/j.bmcl.2020.127393_b0125","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4155\/fmc.14.72","article-title":"Quantification of frequent-hitter behavior based on historical high-throughput screening data","volume":"6","author":"Nissink","year":"2014","journal-title":"Future Med Chem"},{"issue":"11","key":"10.1016\/j.bmcl.2020.127393_b0130","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.4155\/fmc.14.60","article-title":"The essential roles of chemistry in high-throughput screening triage","volume":"6","author":"Dahlin","year":"2014","journal-title":"Future Med Chem"},{"issue":"14","key":"10.1016\/j.bmcl.2020.127393_b0135","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.4155\/fmc.15.121","article-title":"The importance of triaging in determining the quality of output from high-throughput screening","volume":"7","author":"Jones","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmcl.2020.127393_b0140","first-page":"1135","article-title":"Spotting and designing promiscuous ligands for drug discovery","volume":"52","author":"Schneider","year":"2016","journal-title":"ChemComm"},{"key":"10.1016\/j.bmcl.2020.127393_b0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bmcl.2015.11.031","article-title":"Identification of ABIs at potent JAK1 selective inhibitors","volume":"26","author":"Vasbinder","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2020.127393_b0150","unstructured":"See supplementary information for % inhibition of all kinases inhibited by \u226570% at 1 \u03bcM compound concentration of compounds 7-9 and for the metabolite identification data for compound 10.in rat hepatocytes and human liver microsomes."},{"issue":"20","key":"10.1016\/j.bmcl.2020.127393_b0155","first-page":"9030","article-title":"Kinase inhibitors for the treatment of immunological disorders","volume":"61","author":"Bryan","year":"2018","journal-title":"Recent Adv"},{"issue":"2","key":"10.1016\/j.bmcl.2020.127393_b0160","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/jcb.26293","article-title":"CDK9: a key player in cancer and other diseases","volume":"119","author":"Franco","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bmcl.2020.127393_b0165","doi-asserted-by":"crossref","first-page":"10414","DOI":"10.1021\/jm301367c","article-title":"Rational design of highly selective spleen tyrosine kinase inhibitors","volume":"55","author":"Lucas","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2020.127393_b0170","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2020.127393_b0175","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/13543770903207039","article-title":"Therapeutic prospect of SYK inhibitors","volume":"19","author":"Ruzza","year":"2009","journal-title":"Exp Opin Ther Pat"},{"key":"10.1016\/j.bmcl.2020.127393_b0180","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/13543776.2014.890184","article-title":"Spleen tyrosine kinase inhibitors: a review of the patent literature. 2010\u20132013","volume":"24","author":"Norman","year":"2014","journal-title":"Exp Opin Ther Pat"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20305047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20305047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:35:39Z","timestamp":1760772939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X20305047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":36,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0960894X20305047"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127393","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"127393"}}